13.45

3.22% 0.42

After Hours: 13.45

Edgewise Therapeutics Inc (EWTX)

Overview News Price History Option Chain Financials Discussions Forecast

Edgewise Therapeutics Inc stock is traded at $13.45, with a volume of 990.80K. It is up +3.22% in the last 24 hours and down -49.11% over the past month. Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.

Previous Close:

$13.03

Open:

$12.98

24h Volume:

990.80K

Relative Volume:

0.58

Market Cap:

$1.30B

Revenue:

Net Income/Loss:

$-115.88M

P/E Ratio:

-8.6954

EPS:

-1.5468

Net Cash Flow:

$-104.72M

1W Performance:

+16.25%

1M Performance:

-49.11%

6M Performance:

-62.12%

1Y Performance:

-14.06%

1-Day Range:

$12.61

$13.57

1-Week Range:

$11.28

$13.60

52-Week Range:

$10.60

$38.12

Edgewise Therapeutics Inc Stock (EWTX) Company Profile

Name

Edgewise Therapeutics Inc

Sector

Healthcare (1151)

Industry

Biotechnology (660)

Phone

720-262-7002

Address

1715 38TH ST, BOULDER

Employee

110

Twitter

Next Earnings Date

2025-03-03

Latest SEC Filings

EWTX's Discussions on Twitter

Compare EWTX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
EWTX Edgewise Therapeutics Inc	13.45	1.30B	0	-115.88M	-104.72M	-1.5468
VRTX Vertex Pharmaceuticals Inc	489.10	127.47B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	563.16	62.43B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	596.20	37.03B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	234.56	31.06B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	230.98	26.16B	3.81B	-644.79M	-669.77M	-6.24

Edgewise Therapeutics Inc Stock (EWTX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-02-25	Downgrade	Scotiabank	Sector Outperform → Sector Perform
Mar-07-25	Initiated	Scotiabank	Sector Outperform
Jan-22-25	Initiated	Stifel	Hold
Nov-22-24	Initiated	Evercore ISI	Outperform
Mar-07-24	Initiated	Piper Sandler	Overweight
May-01-23	Initiated	Truist	Buy
Aug-25-22	Downgrade	Goldman	Neutral → Sell
Apr-13-22	Initiated	RBC Capital Mkts	Outperform
Jan-28-22	Initiated	Goldman	Neutral

View All

Edgewise Therapeutics Inc Stock (EWTX) Latest News

Apr 18, 2025

New Leaf Venture Partners L.L.C. Has $27.51 Million Position in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat

Apr 18, 2025

Apr 17, 2025

Edgewise Therapeutics (NASDAQ:EWTX) Stock Price Up 9.4%Here's What Happened - MarketBeat

Apr 17, 2025

Norges Bank Acquires New Position in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat

Apr 17, 2025

Apr 16, 2025

(EWTX) Technical Pivots with Risk Controls - news.stocktradersdaily.com

Apr 16, 2025

Apr 14, 2025

Trexquant Investment LP Invests $2 Million in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat

Apr 14, 2025

Apr 13, 2025

Edgewise Therapeutics (NASDAQ:EWTX) Reaches New 52-Week LowHere's What Happened - MarketBeat

Apr 13, 2025

Vanguard Group Inc. Sells 49,214 Shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat

Apr 13, 2025

Apr 12, 2025

Leerink Partnrs Issues Optimistic Outlook for EWTX Earnings - MarketBeat

Apr 12, 2025

Schroder Investment Management Group Acquires Shares of 93,061 Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat

Apr 12, 2025

Apr 11, 2025

Wedbush Reduces Earnings Estimates for Edgewise Therapeutics - MarketBeat

Apr 11, 2025

Apr 10, 2025

Cytokinetics rises as Edgewise posts mid-stage trial data for heart disorder therapy - MSN

Apr 10, 2025

Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In Q2 - Benzinga

Apr 10, 2025

The Zacks Analyst Blog Highlights Pacira Biosciences, Edgewise, Sarepta Therapeutics, Amgen and Bristol Myers Squibb - Yahoo Finance

Apr 10, 2025

Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Director Orbimed Advisors Llc Purchases 496,771 Shares - MarketBeat

Apr 10, 2025

Cinctive Capital Management LP Cuts Stock Position in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat

Apr 10, 2025

Apr 09, 2025

Edgewise Therapeutics (NASDAQ:EWTX) Sees Large Volume IncreaseStill a Buy? - MarketBeat

Apr 09, 2025

Apr 08, 2025